- Home
- INO vs BAFN Comparison
INO vs BAFN Comparison
Compare INO & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- BAFN
- Stock Information
- Founded
- INO 1979
- BAFN 1999
- Country
- INO United States
- BAFN United States
- Employees
- INO N/A
- BAFN N/A
- Industry
- INO Medical/Dental Instruments
- BAFN Savings Institutions
- Sector
- INO Health Care
- BAFN Finance
- Exchange
- INO Nasdaq
- BAFN Nasdaq
- Market Cap
- INO 75.4M
- BAFN 70.2M
- IPO Year
- INO 1998
- BAFN N/A
- Fundamental
- Price
- INO $2.24
- BAFN $18.33
- Analyst Decision
- INO Buy
- BAFN
- Analyst Count
- INO 6
- BAFN 0
- Target Price
- INO $17.00
- BAFN N/A
- AVG Volume (30 Days)
- INO 739.9K
- BAFN 7.4K
- Earning Date
- INO 03-05-2025
- BAFN 01-30-2025
- Dividend Yield
- INO N/A
- BAFN 1.71%
- EPS Growth
- INO N/A
- BAFN 134.19
- EPS
- INO N/A
- BAFN 2.62
- Revenue
- INO $203,413.00
- BAFN $83,769,000.00
- Revenue This Year
- INO N/A
- BAFN N/A
- Revenue Next Year
- INO $1,970.14
- BAFN N/A
- P/E Ratio
- INO N/A
- BAFN $7.08
- Revenue Growth
- INO N/A
- BAFN 10.60
- 52 Week Low
- INO $1.74
- BAFN $10.40
- 52 Week High
- INO $14.75
- BAFN $19.21
- Technical
- Relative Strength Index (RSI)
- INO 54.46
- BAFN 74.17
- Support Level
- INO $1.82
- BAFN $16.25
- Resistance Level
- INO $2.31
- BAFN $19.21
- Average True Range (ATR)
- INO 0.14
- BAFN 0.82
- MACD
- INO 0.05
- BAFN 0.15
- Stochastic Oscillator
- INO 83.17
- BAFN 77.89
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.